Multicenter Open Label Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients with Brain Metastasis due to HR+/Her2- Breast Cancer
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Criterium, Inc
Start Date
December 9, 2021
End Date
December 31, 2026
Administered By
Duke Cancer Institute
Awarded By
Criterium, Inc
Start Date
December 9, 2021
End Date
December 31, 2026